Einleitung

Aus Hl7wiki
(Teildokument von Pathologiebefund)
Wechseln zu: Navigation, Suche
(Einleitung)
(Foreword)
 
(659 dazwischenliegende Versionen von 4 Benutzern werden nicht angezeigt)
Zeile 1: Zeile 1:
 
{{DocumentPart}}
 
{{DocumentPart}}
  
=Einleitung / Introduction=
+
=Foreword=
  
Dieses Dokument ist ein Entwurf für die Umsetzung von Pathologie-Berichten mit Hilfe von HL7 CDA R2. Diese Entwicklung soll die Pathologieintegration innerhalb Deutschlands, im deutschsprachigen Raum und auch international fördern. Sie wird vom Bundesverband Deutscher Pathologen e.V. unterstützt.
+
This is a supplement to the IHE Pathology
 +
and Laboratory Medicine Technical Framework V8.0. Each supplement undergoes a
 +
process of public comment and trial implementation before being incorporated
 +
into the volumes of the Technical Frameworks.
  
Ausgehend vom HL7 V3 Arztbrief-Leitfaden der bvitg (ehemals VHitG) stützt sich der Pathologiebefund auf die IHE-Dokumente "IHE Anatomic Pathology, Technical Framework Supplement, Anatomic Pathology Structured Reports - Trial Implementation, Rev.2.0" vom 06.08.2013, "APSR Value Sets Appendix, Rev. 2.0" vom 06.08.2013, "IHE Anatomic Pathology (PAT), Technical Framework, Volume 1, Revision 2.0 1, Trial Implementation" vom 23.7.2010, "IHE Anatomic Pathology (PAT), Technical Framework, Volume 2 15, Revision 2.0, Trial Implementation" vom 23.7.2010.
+
This supplement was published on September 27, 2017 for Public Comment, with a comment period extending to mid-November. The current content is the Trial Implementation version, which has taken in consideration the comments received.
  
Die spezifisch deutschen Belange werden als National Extensions für IHE entwickelt und mit den Aktivitäten von ELGA, Österreich, abgestimmt. Darüber hinaus wird eine enge Kooperation mit IHE-AP und HL7-AP gesucht, um die in Deutschland erarbeiteten Details international einzubringen.
+
This supplement describes changes to the
 +
existing technical framework documents.  
  
Orientiert wird dabei auf eine möglichst vollständige Berücksichtigung des "Leitfadens Pathologie/Neuropathologie (ehem. TM-30)" des Sektorkomitees Pathologie für die Anwendung der DIN EN ISO/IEC 17020 in der Pathologie/Neuropathologie.
+
“Boxed” instructions like the sample
 +
below indicate to the Volume Editor how to integrate the relevant section(s)
 +
into the relevant Technical Framework volume.
  
Weiterhin wird angestrebt, die durch den Bundesverband Deutscher Pathologen und die Deutsche Gesellschaft für Pathologie veröffentlichten "Empfehlungen zur pathologisch-anatomischen Diagnostik von Kolorektalen Karzinomen, Mammakarzinomen und Prostatakarzinomen" in HL7 CDA R2 kompatible Templates zur Integration als Checklisten in Pathologie-Management-Systeme umzusetzen.  
+
<syntaxhighlight lang="xml">
 +
Replace Section X.X by the following:
 +
</syntaxhighlight>
  
Auf dieser Basis soll der Import von HL7 CDA R2 Dokumenten von der Pathologie in KIS-Systeme sowie in Tumormeldungen und Qualitätssicherungs- und Tumordokumentationssysteme (z.B. AQUA, MaSC, ix.mid etc.) umgesetzt werden.
+
Where the amendment adds text, make the added
 +
text '''bold underline'''. Where the amendment removes
 +
text, make the removed text '''bold strikethrough'''.
 +
When entire new sections are added, introduce with editor’s instructions to
 +
“add new text” or similar, which for readability are not bolded or underlined.
  
 +
General information about IHE can be found at: http://www.ihe.net.
  
 +
Information about the IHE Pathology and Laboratory Medicine domain can be found at: http://ihe.net/IHE_Domains.
  
This document is a proposal for Anatomical Pathology Structured Reports (APSR)in HL7 CDA R2. It should help to integrate Anatomic and Clinical Pathology in German speaking countries into clinical and research environments by enabling interoperability between a variety of LIS, HIS, and cancer registries as well as elctronic health records. The specific German aspects are constraints of the IHE Anatomic Pathology profiles. They will be developed in close collaboration with the Austrian ELGA initiative. On the other hand, there is a close cooperation with IHE-AP and HL7-AP as to bring in the national demands into international standard development.
+
Information about the structure of IHE Technical Frameworks and Supplements can be found at: http://ihe.net/IHE_Process and http://ihe.net/Profiles.  
  
For the German APSR the "Guideline Pathology / Neuropathology" (formerly TM-30) of the Sector Committee Pathology for the implementation of DIN EN ISO/EC 17020 shall be regarded. Furthermore, the recommendations of the German Society of Pathology for pathologic-anatomical reporting of colorectal, breast, and prostate cancers should be enabled by CDA compatible codes and value sets.
+
The current version of the IHE Technical Framework (if applicable) can be found at: http://ihe.net/Technical_Frameworks.
  
==Grundlage==
+
''Comments may be submitted on IHE Technical Framework templates any time at http://ihe.net/ihetemplates.cfm. Please enter comments/issues as soon as they are found. Do not wait until a future review cycle is announced.''
Grundlage dieses Konzeptes ist der Implementierungsleitfaden des Bundesverbands der Hersteller von IT-Lösungen für das Gesundheitswesen, e.V. ([http://www.bvitg.de bvitg]), Berlin, für den Arztbrief des deutschen Gesundheitswesens sowie der Diagnose- und Datentypleitfaden.
 
  
* bvitG Arztbrief, v2.x, <nowiki>[CDAr2Arztbrief]</nowiki>, 2012
+
=Acknowledgements=
* [http://www.hl7.de/download/documents/diagnosen/Diagnoseleitfaden-v1.1_20110622.pdf Diagnoseleitfaden] v0.99b, 13.12.09
 
* Datentypleitfaden (HL7 V3)
 
  
 +
Following authors mainly contributed to this document:
 +
*Francois Macary, PHAST, Paris
 +
*Dr. Gunter Haroske, Federal Association of German Pathologists, Berlin
 +
*Dr. Frank Oemig, Deutsche Telekom Healthcare Solutions GmbH, Bonn
 +
*Dr. Riki Merrick, APHL, San Francisco
 +
*Dr. Raj Dash, Duke University, Durham
  
 +
They have to acknowledge the contributions of Dr. Kai U. Heitmann, who managed the cooperation between PaLM and ART-DECOR. It was the very first time that a complete IHE TF document could be developed by means of the ART-DECOR tools and a media wiki.
  
==Basics==
+
__TOC__
The APSR Germany is based on the trial implementation of the Bundesverband der Hersteller von IT-Lösungen für das Gesundheitswesen, e.V. ([http://www.bvitg.de bvitg]), Berlin, for the Discharge letter ("Arztbrief") of the German Health System, as well as the guidelines for diagnosis and data types.
 
  
* bvitG Arztbrief, v2.x, <nowiki>[CDAr2Arztbrief]</nowiki>, 2012
+
=Introduction to this Supplement=
* [http://www.hl7.de/download/documents/diagnosen/Diagnoseleitfaden-v1.1_20110622.pdf Diagnoseleitfaden] v0.99b, 13.12.09
 
* Datentypleitfaden (HL7 V3)
 
  
==Disclaimer==
+
This supplement complements volume 1 of
Dieses Dokument enthält keine komplette Spezifikation eines HL7 CDA R2 Arztbriefes bzw. Dokumentes. Es werden Teile eines Arztbriefes spezifiziert.
+
the PaLM technical framework with the description of the APSR 2.0 content
 +
profile, and volume 3 with the bindings, content modules and value sets, which specify
 +
this profile.
  
 +
==Open Issues and Questions==
  
[[Kategorie:cdapath|Einleitung]]
+
''None yet''
 +
 
 +
==Closed Issues==
 +
 
 +
'''APSR-07 – Representing the hierarchy of specimens in an entry''' : This APSR
 +
supplement enables to represent the hierarchy of specimens at the CDA level 3.
 +
The operations on specimen and production of child specimens are tracked in the
 +
“Procedure Steps” section, which has a level 3 entry.
 +
 
 +
'''APSR-10 – Observation related to multiple specimens''': For example tumor staging may require combining data from multiple specimens (e.g., a breast excision with positive margins followed by a re-excision with clear margins – in this case the tumor size may be a composite of measurements from both specimens. Another example is staging of ovarian carcinomas with multiple biopsies of pelvis, peritoneum, nodes, omentum, etc.). To accommodate these use
 +
cases, each problem organizer as well as each observation may reference any number of specimens using the <specimen> child element. Each of these references may point to a detailed description of the specimen, in the "procedure steps" section.
 +
 
 +
'''APSR-11 – Derivative specimens''':Specimens
 +
derived from primary specimens for ancillary studies, which may be sent to a
 +
reference lab or done in another part of the same institution, are included in
 +
the scope of this profile. The results produced on a derived specimen are
 +
attached to this specimen in the report.

Aktuelle Version vom 7. Februar 2018, 11:17 Uhr

Dieses Material ist Teil des Leitfadens Pathologiebefund.
  • Direkt im Wiki geändert werden sollten Schreibfehler, ergänzende Hinweise.
  • Offene Fragen, die der Diskussionen bedürfen, sollten auf der Diskussionsseite aufgenommen werden.
  • Liste der Seiten dieses Leitfadens: hier, Liste der Seiten, in denen dieses Material verwendet (transkludiert) siehe hier .

Foreword

This is a supplement to the IHE Pathology and Laboratory Medicine Technical Framework V8.0. Each supplement undergoes a process of public comment and trial implementation before being incorporated into the volumes of the Technical Frameworks.

This supplement was published on September 27, 2017 for Public Comment, with a comment period extending to mid-November. The current content is the Trial Implementation version, which has taken in consideration the comments received.

This supplement describes changes to the existing technical framework documents.

“Boxed” instructions like the sample below indicate to the Volume Editor how to integrate the relevant section(s) into the relevant Technical Framework volume.

Replace Section X.X by the following:

Where the amendment adds text, make the added text bold underline. Where the amendment removes text, make the removed text bold strikethrough. When entire new sections are added, introduce with editor’s instructions to “add new text” or similar, which for readability are not bolded or underlined.

General information about IHE can be found at: http://www.ihe.net.

Information about the IHE Pathology and Laboratory Medicine domain can be found at: http://ihe.net/IHE_Domains.

Information about the structure of IHE Technical Frameworks and Supplements can be found at: http://ihe.net/IHE_Process and http://ihe.net/Profiles.

The current version of the IHE Technical Framework (if applicable) can be found at: http://ihe.net/Technical_Frameworks.

Comments may be submitted on IHE Technical Framework templates any time at http://ihe.net/ihetemplates.cfm. Please enter comments/issues as soon as they are found. Do not wait until a future review cycle is announced.

Acknowledgements

Following authors mainly contributed to this document:

  • Francois Macary, PHAST, Paris
  • Dr. Gunter Haroske, Federal Association of German Pathologists, Berlin
  • Dr. Frank Oemig, Deutsche Telekom Healthcare Solutions GmbH, Bonn
  • Dr. Riki Merrick, APHL, San Francisco
  • Dr. Raj Dash, Duke University, Durham

They have to acknowledge the contributions of Dr. Kai U. Heitmann, who managed the cooperation between PaLM and ART-DECOR. It was the very first time that a complete IHE TF document could be developed by means of the ART-DECOR tools and a media wiki.

Introduction to this Supplement

This supplement complements volume 1 of the PaLM technical framework with the description of the APSR 2.0 content profile, and volume 3 with the bindings, content modules and value sets, which specify this profile.

Open Issues and Questions

None yet

Closed Issues

APSR-07 – Representing the hierarchy of specimens in an entry : This APSR supplement enables to represent the hierarchy of specimens at the CDA level 3. The operations on specimen and production of child specimens are tracked in the “Procedure Steps” section, which has a level 3 entry.

APSR-10 – Observation related to multiple specimens: For example tumor staging may require combining data from multiple specimens (e.g., a breast excision with positive margins followed by a re-excision with clear margins – in this case the tumor size may be a composite of measurements from both specimens. Another example is staging of ovarian carcinomas with multiple biopsies of pelvis, peritoneum, nodes, omentum, etc.). To accommodate these use cases, each problem organizer as well as each observation may reference any number of specimens using the <specimen> child element. Each of these references may point to a detailed description of the specimen, in the "procedure steps" section.

APSR-11 – Derivative specimens:Specimens derived from primary specimens for ancillary studies, which may be sent to a reference lab or done in another part of the same institution, are included in the scope of this profile. The results produced on a derived specimen are attached to this specimen in the report.